ClinicalTrials.gg
RecruitingNCT06399835Updated May 5, 2026

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

A Phase 4 interventional study of Enavogliflozin and Pioglitazone in Type 2 Diabetes, sponsored by Seoul National University Bundang Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Seoul National University Bundang Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
10th of 15
120 · median 140
Started
2024
with 1 other
Phase 4
3 of 15
3 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Seoul National University Bundang Hospital

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 10th largest by planned enrollment, is one of 2 that started in 2024, is one of 3 in phase 4, and was the 12th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors. Additionally, the study will compare changes in other metabolic or cardiovascular risk factors, such as triglycerides, high density lipoprotein cholesterol (HDLc), uric acid, blood pressure, and inflammatory markers, between the two drugs.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes patients with a (HbA1c) level of 7.0 - 10.5% at screening
  • Males or females aged 20-80 years
  • Individuals who have been taking Metformin (≥ 500mg) with or without a DPP-4 inhibitor (such as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Alogliptin, Teneligliptin, Anagliptin, Evogliptin) for at least the past 3 months
  • ≥ 23 kg/m²
  • Estimated glomerular filtration ratio () ≥ 60 ml/min/1.73m²

Exclusion criteria

Exclusion Criteria:

  • Patients with Type 1 Diabetes, Gestational Diabetes, or secondary diabetes due to other causes
  • Patients with a history of acute cardiovascular disease within the last 3 months prior to the screening visit
  • Pregnant or breastfeeding patients, or patients not using . Patients with chronic or C (excluding healthy carriers of Hepatitis B), or liver disease ( (AST) and/or alanine aminotransferase (ALT) > 3 times the )
  • Patients with heart failure or a history of heart failure
  • Individuals with a history of cancer within the past 5 years (excluding those adequately treated for squamous cell carcinoma or thyroid cancer)
  • Patients who have participated in another clinical study within the last 30 days
  • Alcohol addiction
  • Patients for whom the use of Enavogliflozin or Pioglitazone is
  • Patients taking other oral hypoglycemic agents or insulin or other drugs
  • Patients deemed unsuitable for the study based on the investigator's judgment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin

    Enavogliflozin 0.3 mg

    Drug: Enavogliflozin

  • Active comparator
    Pioglitazone

    Pioglitazone 15 mg

    Drug: Pioglitazone

Interventions

  • Enavogliflozin 0.3mg once daily

    Also known as: Envlo Tab.

  • Pioglitazone 15mg once daily

    Also known as: Actos Tab.

06

What researchers measure

Primary outcomes

  1. Changes of HbA1c from the baseline

    %

    Time frame: 24 weeks

Secondary outcomes

  1. Patients achieving HbA1c levels below 7%

    N and percentage of the patients

    Time frame: 24 weeks

  2. Changes of body fat (whole body fat, abdominal fat)

    kg, %; measured with bioelectrical impedance analysis

    Time frame: 24 weeks

  3. Changes of body weight

    Time frame: 12 weeks, 24 weeks

  4. Changes of glucose levels (fasting, 2-hour postprandial)

    mg/dL

    Time frame: 12 weeks, 24 weeks

  5. Changes of systolic/diastolic blood pressures

    mmHg

    Time frame: 12 weeks, 24 weeks

  6. Changes of lipids (total cholesterol, HDLc, low density lipoprotein cholesterol [LDLc], triglycerides)

    mg/dL

    Time frame: 12 weeks, 24 weeks

  7. Changes of electrolytes (uric acid)

    mg/dL

    Time frame: 12 weeks, 24 weeks

  8. Changes in parathyroid hormone

    pg/mL

    Time frame: 12 weeks, 24 weeks

  9. Changes in 25-hydroxyl vitamin D3

    ng/mL

    Time frame: 12 weeks, 24 weeks

  10. Changes of albuminuria

    mg/g

    Time frame: 12 weeks, 24 weeks

  11. Changes of urine electrolytes (Na, K, Cl, Ca, P, glucose)

    mg/dL

    Time frame: 12 weeks, 24 weeks

  12. Changes in ketone body

    umol/L

    Time frame: 12 weeks, 24 weeks

  13. Changes of carotid intima-media thickness

    maximal thickness (mm)

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 34 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 6, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06399835
Responsible party
Soo Lim (Professor, Seoul National University Bundang Hospital) — Principal investigator
First posted
May 6, 2024
Start date
Feb 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 5, 2026

Study contacts

Soo Lim, M.D. Ph.D.
Contact
limsoo@snu.ac.kr
+82317877035
Minji Sohn, Ph.D.
Contact
rainbowmjs@naver.com
+82317878443
Soo Lim, M.D. Ph.D.
principal investigator · Seoul National University Bundang Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion